After being selected to provide the self-tests necessary for the screening campaign set up by the Confederation, Roche signed a contract to deliver treatment against covid to Switzerland. It is a combination of monoclonal antibodies, casirivimab and imdevimab, developed by the American company Regeneron in partnership with the Basel laboratory. The announcement, made public by the Federal Office of Public Health on Tuesday morning, reports an order for 3,000 doses, but the amount of the operation was not disclosed.
At the end of January, Germany acquired 200,000 doses for an amount of 400 million euros, a price of 2,000 euros (2,200 francs) per dose. Two weeks earlier, the US government had ordered 1.25 million doses, delivery of which is expected in June. The first doses for Switzerland are due in mid-May. If its exact price is not known, it is an expensive treatment, the cost of which will be borne by the Confederation initially.